The similarity in structure between brequinar, a clinical trial drug for cancer, and the FSP1 inhibitor iFSP1 led to the hypothesis of off-target effects, which was supported when brequinar was found to inhibit FSP1 at high concentrations and fit into FSP1’s CoQ10-binding pocket. The gene discussed is AIFM2; the disease is cancer.